Tumor Biology

, Volume 34, Issue 6, pp 3831–3837 | Cite as

The cyclin D1 (CCND1) G870A polymorphism and lung cancer susceptibility: a meta-analysis

  • Changxi Zhou
  • Huaijie An
  • Mingdong Hu
  • Qinghui Liu
  • Peiliang Geng
  • Jiancheng Xu
  • Baojun Sun
  • Changting Liu
Research Article


Several studies have investigated the association between Cyclin D1 (CCND1) G870A genetic polymorphism and lung cancer susceptibility, but the results were inconclusive. The aim of this meta-analysis was to summarize available evidence for such a relationship. The reviewers made use of MEDLINE, EMBASE, and BIOSIS databases. The relevant data were independently extracted by two reviewers. The odds ratio (OR) with 95 % confidence interval (CI) was selected as the principal outcome measure. The heterogeneity test, the publication bias test, and the sensitivity analysis were performed. Overall, a total of 10 case–control studies were included. Our meta-analysis indicated that CCND1 G870A genetic polymorphism was a risk factor for lung cancer under homozygote model (OR = 1.18; 95 % CI = 1.02, 1.37), recessive model (OR = 1.21; 95 % CI = 1.03, 1.41), and allele model (OR = 1.11; 95 % CI = 1.02, 1.21). In the subgroup analysis by source of ethnicity, a statistical increase of lung cancer risk was found among Asian groups for allele model (OR = 1.11; 95 % CI = 1.01–1.22). The present meta-analysis suggests that CCND1 G870A polymorphism may be a risk factor for lung cancer. Besides, allele A may contribute to increased lung cancer risk.


CCND1 Polymorphism Lung cancer Meta-analysis 


  1. 1.
    Jemal A et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRefGoogle Scholar
  2. 2.
    Ferlay J et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.PubMedCrossRefGoogle Scholar
  3. 3.
    Pharoah PD et al. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer. 2004;4(11):850–60.PubMedCrossRefGoogle Scholar
  4. 4.
    Asami S et al. Increase of a type of oxidative DNA damage, 8-hydroxyguanine, and its repair activity in human leukocytes by cigarette smoking. Cancer Res. 1996;56(11):2546–9.PubMedGoogle Scholar
  5. 5.
    Ceschi M et al. The effect of cyclin D1 (CCND1) G870A-polymorphism on breast cancer risk is modified by oxidative stress among Chinese women in Singapore. Carcinogenesis. 2005;26(8):1457–64.PubMedCrossRefGoogle Scholar
  6. 6.
    Forsti A et al. Single nucleotide polymorphisms in breast cancer. Oncol Rep. 2004;11(4):917–22.PubMedGoogle Scholar
  7. 7.
    Hunter DJ et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007;39(7):870–4.PubMedCrossRefGoogle Scholar
  8. 8.
    Krippl P et al. The 870G>A polymorphism of the cyclin D1 gene is not associated with breast cancer. Breast Cancer Res Treat. 2003;82(3):165–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Onay VU et al. SNP-SNP interactions in breast cancer susceptibility. BMC Cancer. 2006;6:114.PubMedCrossRefGoogle Scholar
  10. 10.
    Shu XO et al. Association of cyclin D1 genotype with breast cancer risk and survival. Cancer Epidemiol Biomarkers Prev. 2005;14(1):91–7.PubMedGoogle Scholar
  11. 11.
    Yu CP et al. Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1. Breast Cancer Res Treat. 2008;107(1):95–102.PubMedCrossRefGoogle Scholar
  12. 12.
    Bala S, Peltomaki P. CYCLIN D1 as a genetic modifier in hereditary nonpolyposis colorectal cancer. Cancer Res. 2001;61(16):6042–5.PubMedGoogle Scholar
  13. 13.
    Grieu F et al. Lack of association between CCND1 G870A polymorphism and the risk of breast and colorectal cancers. Anticancer Res. 2003;23(5b):4257–9.PubMedGoogle Scholar
  14. 14.
    Grunhage F et al. Association of familial colorectal cancer with variants in the E-cadherin (CDH1) and cyclin D1 (CCND1) genes. Int J Colorectal Dis. 2008;23(2):147–54.PubMedCrossRefGoogle Scholar
  15. 15.
    Hong Y et al. GG genotype of cyclin D1 G870A polymorphism is associated with increased risk and advanced colorectal cancer in patients in Singapore. Eur J Cancer. 2005;41(7):1037–44.PubMedCrossRefGoogle Scholar
  16. 16.
    Huang WS et al. Impact of the cyclin D1 A870G polymorphism on susceptibility to sporadic colorectal cancer in Taiwan. Dis Colon Rectum. 2006;49(5):602–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Jiang J et al. Elevated risk of colorectal cancer associated with the AA genotype of the cyclin D1 A870G polymorphism in an Indian population. J Cancer Res Clin Oncol. 2006;132(3):193–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Kong S et al. Cyclin D1 polymorphism and increased risk of colorectal cancer at young age. J Natl Cancer Inst. 2001;93(14):1106–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Geddert H et al. Polymorphism of p16 INK4A and cyclin D1 in adenocarcinomas of the upper gastrointestinal tract. J Cancer Res Clin Oncol. 2005;131(12):803–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Song JH et al. Association of cyclin D1 G870A polymorphism with susceptibility to gastric cancers in Korean male patients. Neoplasma. 2007;54(3):235–9.PubMedGoogle Scholar
  21. 21.
    Koike H et al. Cyclin D1 gene polymorphism and familial prostate cancer: the AA genotype of A870G polymorphism is associated with prostate cancer risk in men aged 70 years or older and metastatic stage. Anticancer Res. 2003;23(6D):4947–51.PubMedGoogle Scholar
  22. 22.
    Wang L et al. Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer. 2003;103(1):116–20.PubMedCrossRefGoogle Scholar
  23. 23.
    Casson AG et al. Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma. Cancer. 2005;104(4):730–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Jain M et al. Role of BCL2 (ala43thr), CCND1 (G870A) and FAS (A-670G) polymorphisms in modulating the risk of developing esophageal cancer. Cancer Detect Prev. 2007;31(3):225–32.PubMedCrossRefGoogle Scholar
  25. 25.
    Yu C et al. Lack of association between CCND1 G870A polymorphism and risk of esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2003;12(2):176.PubMedGoogle Scholar
  26. 26.
    Zhang J et al. Association of cyclin D1 (G870A) polymorphism with susceptibility to esophageal and gastric cardiac carcinoma in a northern Chinese population. Int J Cancer. 2003;105(2):281–4.PubMedCrossRefGoogle Scholar
  27. 27.
    Ito M et al. Polymorphism within the cyclin D1 gene is associated with an increased risk of carcinoma in situ in patients with superficial bladder cancer. Urology. 2004;64(1):74–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Ryk C et al. Influence of polymorphism in DNA repair and defence genes on p53 mutations in bladder tumours. Cancer Lett. 2006;241(1):142–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Sanyal S et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis. 2004;25(5):729–34.PubMedCrossRefGoogle Scholar
  30. 30.
    Wang L et al. Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis. 2002;23(2):257–64.PubMedCrossRefGoogle Scholar
  31. 31.
    Yu J et al. Association of the cyclin D1 gene G870A polymorphism with susceptibility to sporadic renal cell carcinoma. J Urol. 2004;172(6 Pt 1):2410–3.PubMedCrossRefGoogle Scholar
  32. 32.
    Lammie GA et al. D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene. 1991;6(3):439–44.PubMedGoogle Scholar
  33. 33.
    Chen X et al. CCND1 G870A polymorphism with altered cyclin D1 transcripts expression is associated with the risk of glioma in a Chinese population. DNA Cell Biol. 2012;31(6):1107–13.PubMedCrossRefGoogle Scholar
  34. 34.
    Sherr CJ. D-type cyclins. Trends Biochem Sci. 1995;20(5):187–90.PubMedCrossRefGoogle Scholar
  35. 35.
    Sherr CJ. Cancer cell cycles. Science. 1996;274(5293):1672–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Betticher DC et al. Alternate splicing produces a novel cyclin D1 transcript. Oncogene. 1995;11(5):1005–11.PubMedGoogle Scholar
  37. 37.
    Betticher DC et al. Abnormal expression of CCND1 and RB1 in resection margin epithelia of lung cancer patients. Br J Cancer. 1997;75(12):1761–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Kim ES, Lee JJ, Wistuba II. Cotargeting cyclin D1 starts a new chapter in lung cancer prevention and therapy. Cancer Prev Res (Phila). 2011;4(6):779–82.CrossRefGoogle Scholar
  39. 39.
    Gautschi O et al. Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer. 2007;55(1):1–14.PubMedCrossRefGoogle Scholar
  40. 40.
    Qiuling S et al. Cyclin D1 gene polymorphism and susceptibility to lung cancer in a Chinese population. Carcinogenesis. 2003;24(9):1499–503.PubMedCrossRefGoogle Scholar
  41. 41.
    Hsia TC et al. Interaction of CCND1 genotype and smoking habit in Taiwan lung cancer patients. Anticancer Res. 2011;31(10):3601–5.PubMedGoogle Scholar
  42. 42.
    Sobti RC et al. Effects of cyclin D1 (CCND1) polymorphism on susceptibility to lung cancer in a North Indian population. Cancer Genet Cytogenet. 2006;170(2):108–14.PubMedCrossRefGoogle Scholar
  43. 43.
    Buch S et al. Association of polymorphisms in the cyclin D1 and XPD genes and susceptibility to cancers of the upper aero-digestive tract. Mol Carcinog. 2005;42(4):222–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Gautschi O et al. Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients. Lung Cancer. 2006;51(3):303–11.PubMedCrossRefGoogle Scholar
  45. 45.
    Hung RJ et al. Sequence variants in cell cycle control pathway, X-ray exposure, and lung cancer risk: a multicenter case–control study in Central Europe. Cancer Res. 2006;66(16):8280–6.PubMedCrossRefGoogle Scholar
  46. 46.
    Wang W et al. Genetic variants in cell cycle control pathway confer susceptibility to lung cancer. Clin Cancer Res. 2007;13(19):5974–81.PubMedCrossRefGoogle Scholar
  47. 47.
    Guan P et al. Association of the hOGG1 Ser326Cys polymorphism with increased lung cancer susceptibility in Asians: a meta-analysis of 18 studies including 7592 cases and 8129 controls. Asian Pac J Cancer Prev. 2011;12(4):1067–72.PubMedGoogle Scholar
  48. 48.
    Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411(6835):366–74.PubMedCrossRefGoogle Scholar
  49. 49.
    Wood RD et al. Human DNA repair genes. Science. 2001;291(5507):1284–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Buch SC et al. Genetic variability in DNA repair and cell cycle control pathway genes and risk of smoking-related lung cancer. Mol Carcinog. 2012;51 Suppl 1:E11–20.PubMedCrossRefGoogle Scholar
  51. 51.
    Liang YW et al. Preclinical activity of simvastatin induces cell cycle arrest in g1 via blockade of cyclin d-cdk4 expression in non-small cell lung cancer (NSCLC). Int J Mol Sci. 2013;14(3):5806–16.PubMedCrossRefGoogle Scholar
  52. 52.
    Yue W et al. Cell cycle protein cyclin Y is associated with human non-small-cell lung cancer proliferation and tumorigenesis. Clin Lung Cancer. 2011;12(1):43–50.PubMedCrossRefGoogle Scholar
  53. 53.
    Camidge DR. Cell cycle-associated kinases as targets for therapy in lung cancer. J Thorac Oncol. 2010;5(12 Suppl 6):S461–2.PubMedCrossRefGoogle Scholar
  54. 54.
    Wang R et al. The association of cyclin d1 (a870g) polymorphism with susceptibility to lung cancer in northern Chinese population. Tumor. 2003;23:364–6. Article in Chinese.Google Scholar
  55. 55.
    Wang Q et al. The relationship between the cyclin d1 (ccnd1) a870g gene polymorphism and non-small cell lung cancer in Yunnan. Med Philos. 2008;29:36–8. Article in Chinese.Google Scholar
  56. 56.
    Li QP et al. Comparative study of polymorphism of cyclin d1 gene in patients with non-small cell lung cancer from Xuanwei and Kunming. Shangdong Yi Yao. 2009;49:1–3. Article in Chinese.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Changxi Zhou
    • 1
  • Huaijie An
    • 2
  • Mingdong Hu
    • 3
  • Qinghui Liu
    • 1
  • Peiliang Geng
    • 4
  • Jiancheng Xu
    • 3
  • Baojun Sun
    • 1
  • Changting Liu
    • 1
  1. 1.Nanlou Respiratory Diseases DepartmentPLA General HospitalBeijingPeople’s Republic of China
  2. 2.Medical Center of Navigation & Aviation of PLANavy General HospitalBeijingPeople’s Republic of China
  3. 3.Institute of Respiration, The Second Affiliated HospitalThe Third Military Medical UniversityChongqingPeople’s Republic of China
  4. 4.Key Laboratory of Oncology, Cancer Center, Division of Internal Medicine, Institute of OncologyChinese PLA General Hospital and Chinese PLA Medical SchoolBeijingPeople’s Republic of China

Personalised recommendations